Ignite Creation Date:
2025-12-25 @ 2:11 AM
Ignite Modification Date:
2026-02-25 @ 7:03 PM
Study NCT ID:
NCT01743560
Status:
COMPLETED
Last Update Posted:
2019-07-18
First Post:
2012-10-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Oestrogen Receptor Positive Advanced Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Breast Neoplasms | View |
| None | Neoplasms | View |
| None | Breast diseases | View |
| None | Skin diseases | View |
| None | Exemestane | View |
| None | Antibiotics, Antineoplastic | View |
| None | Everolimus | View |
| None | Antineoplastic Agents | View |
| None | Therapeutic Uses | View |
| None | Pharmacologic Actions | View |
| None | Immunosuppressive Agents | View |
| None | Physiological Effects of Drugs | View |
| None | Aromatase Inhibitors | View |
| None | Enzyme Inhibitors | View |
| None | Molecular Mechanisms of Pharmacological Action | View |